statements. The following is selected financial information for the fiscal year ended June 30,2023 : KLM Pharmaceutical Industries Statement of Financial Position June 30,2023 he following transactions have occurred at Camden: the bonds' debt and equity components separately. 3. The $4.25 preferred shares were issued in 2021. 4. There are no preferred dividends in arrears, and preferred dividends were not declared in fiscal year 2023. 5. The 1,000,000 common shares were outstanding for the entire 2023 fiscal year. 6. Net income for fiscal year 2023 was $1.5 million, and the average income tax rate was 30%. For the fiscal year ended June 30, 2023, calculate the following for Camden (round to the nearest cent): 1. Basic earnings per share 2. Diluted earnings per share For the toolbar, press ALT+F10 (PC) or ALT+FN+F10 (Mac)